Medlab Clinical Limited announced that it has received and analysed the results of the NanoStatTM bioequivalence trial from Zenith in New Zealand. In work undertaken at main laboratory in Alexandria (post results), The company has improved NanoStatTM (1 mg x 4 sprays), with data now indicating a 2 + times better blood level of free atorvastatin compared to the oral ingested 20 mg tablet, Atorvastatin. Further, the work demonstrated that peak blood concentrations of free Atorvastatin was achieved in approximately 30 minutes, as previously compared to 53 minutes on the oral 20 mg tablet. These improvements focused on modifying the way Atorvastatin is metabolised in the human body. In short, Atorvastatin used in brands like Lipitor® is made up of 2 Atorvastatin molecules bound to a Calcium salt - and it was the Calcium salt that was to be the challenge. To date, the company has devised a way whereby the Calcium salt is cleaved off from the Atorvastatin molecules pre-absorption, and the body metabolises free "NanoCelledTM" Atorvastatin - the nett result is significant improvements in free Atorvastatin in the blood at a lowered administered dose. Medlab's intention was to investigate the potential for a lower dose statin delivered as an oro- buccal spray, being similar to the effects of a stronger dose tablet. The data was extremely interesting, not only did it show a level of bioequivalence, it highlighted several areas of improvement which had previously not been obvious. Moving forward Medlab intends to perfect this technique, develop the product further and look for potential new patents for Atorvastatin in light of the programme findings to date.